BioNTech founders launch a new German biotech venture, signaling continued entrepreneurial drive in mRNA innovation
Executive summary: BioNTech co‑founders Ugur Sahin and Özlem Türeci announced the creation of a new German biotech firm, naming an acquaintance as a prospective board member. The venture indicates the founders' intent to pursue additional mRNA‑based projects, potentially adding competition and innovation to the vaccine and therapeutic sectors.
Who is involved: Ugur Sahin, Özlem Türeci, an unidentified acquaintance (to serve on the board), and Germany as the jurisdiction of incorporation.
Likely next: Formal registration of the company, initial board meetings, and the pursuit of funding or partnership opportunities to define the venture’s research agenda.
Ugur Sahin and Özlem Türeci have disclosed plans for a new company in Germany, with an unnamed acquaintance set to join the board. The move comes amid ongoing discussions about the founders' previous relationship with BioNTech and its intellectual property. While no financial details or product pipeline have been revealed yet, the announcement suggests the founders are seeking to expand their impact beyond the COVID-19 vaccine era.
What's next — scenarios
Base: focus on infectious disease vaccines (50%)
Adds a new mRNA competitor, with modest revenue potential by 2028.
- SEC/German commercial register filing by Oct 2026
- First preclinical data release by Q2 2027
Upside: major pharma partnership (30%)
Accelerates pipeline, potentially generating over €500 m revenue by 2030.
- Partnership announcement within 6 months
- IND filing by end 2027
Downside: regulatory delays (20%)
Slower timeline and limited market impact.
- FDA clinical hold on early candidates
- Missing preclinical milestone Q1 2028
Timeline
- — Biotechnologie: Biontech-Gründer starten neue Firma in Deutschland – ein alter Bekannter soll Vorstand werden (Handelsblatt)
- — Pharma: „Enteignung der eigenen Firma“ – Eklat um das Erbe von Biontech (Handelsblatt)
Analysis — what this means
Sectors affected
- mRNA biotechnology
- vaccine development
Historical parallels
- BioNTech COVID‑19 vaccine received EUA in December 2020
Key entities
Sources
- Biotechnologie: Biontech-Gründer starten neue Firma in Deutschland – ein alter Bekannter soll Vorstand werden — Handelsblatt
- Pharma: „Enteignung der eigenen Firma“ – Eklat um das Erbe von Biontech — Handelsblatt
Related cases
- German real estate price growth decelerates as metropolitan apartment prices stabilize or decline
- German home price growth is slowing, signalling a cooling housing market amid tight affordable supply
- BioNTech founders launch new venture Arife, sparking dispute over patents, finances and staff future
- Meta accelerates hardware ecosystem expansion by launching AI-powered smart glasses with displays in the German market
- German political instability and CDU electoral losses threaten European Union leadership and decision-making
- German economists triple growth forecasts to 1.2% amid positive outlook for the coming years